Share

Seattle Genetics CEO on Q1 earnings, Padcev bladder cancer drug

Seattle Genetics CEO Clay Siegall discussed early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December.
07:49
Fri, May 1 20207:09 PM EDT